| Bioactivity | CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50: 0.24 μM). CDK9-IN-25 has good affinity to the main protease of COVID-19 and has antiviral activity against human coronavirus 229E (IC50: 63.28 μM)[1]. |
| Target | IC50: 0.24 μM (CDK9), 63.28 μM (human Coronavirus 229E) |
| Name | CDK9-IN-25 |
| Formula | C15H16FN5 |
| Molar Mass | 285.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alsfouk AA, et al. New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches. Pharmaceuticals (Basel). 2023 Jul 18;16(7):1018.. |